-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $8 Price Target

Benzinga·05/15/2025 15:46:01
Listen to the news
RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $8 price target.